Zobrazeno 1 - 10
of 588
pro vyhledávání: ''
Autor:
Emily Kessler, Rodrigo Saad-Berreta, Hongwu Zheng, Vikram Deshpande, Krishna S. Tummala, Brandon Nicolay, William Shen, Ramzi Adil, Meng-Ju Wu, Juan Dubrot, Lipika Goyal, Vajira Weeresekara, Amaya Pankaj, Mathias Heikenwalder, Tong Wang, Mirian Fernandez-Vaquero, María García-Beccaria, Ting-Yu Wei, Kira E Olander, Sebastien Ronseaux, Vindhya Vijay, Qibiao Wu, Yuanli Zhen, Christine Hudson, Nabeel Bardeesy, Lei Shi, Rahul M. Kohli, Meiqi Luo, Yi Sun, Russell W. Jenkins, Robert T. Manguso, Cristina R. Ferrone, Joshua Merritt
Publikováno v:
Cancer Discovery. 12:812-835
Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple α-ketoglutarate–dependent enzymes, altering epigenetics and metabolism. Here, by developing mIDH1
Autor:
Ryan C. Gimple, Guoxin Zhang, Linjie Zhao, Leo J.Y. Kim, Jia Z. Shen, Cheryl Kim, Briana C. Prager, Xujun Wang, Jean A. Bernatchez, Xiang-Dong Fu, Jeremy N. Rich, Kailin Yang, Jair L. Siqueira-Neto, Deobrat Dixit, Zhixin Qiu, Lukas Chavez, Zhe Zhu, Deguan Lv, Ye Zheng, Denise Hinz, Zhengyu Liang, Charles Spruck, Xiuxing Wang, Chunyu Jin, Qiyuan Yang, Qiulian Wu, Lihua Min, Katherine A. Jones, Zhen Dong, Shruti Bhargava
Publikováno v:
Cancer Discov
Glioblastoma (GBM) is the most lethal primary brain cancer characterized by therapeutic resistance, which is promoted by GBM stem cells (GSC). Here, we interrogated gene expression and whole-genome CRISPR/Cas9 screening in a large panel of patient-de
Autor:
Becky K. C. Chan, Stephanie Ma, Hoi Yee Chu, Koon Ho Wong, Cindy S.W. Tong, Gigi C. G. Choi, Maggie S. H. Cheung, Tin Lok Wong, Yuanhua Huang, Feng Xu, John H. C. Fong, Alan S.L. Wong, Lakhansing Pardeshi, Man Tong, Kylie Hin-Man Mak
Publikováno v:
Cancer Research. 81:6219-6232
Systematic testing of existing drugs and their combinations is an attractive strategy to exploit approved drugs for repurposing and identifying the best actionable treatment options. To expedite the search among many possible drug combinations, we de
Autor:
Arnab Ray Chaudhuri, Jos Jonkers, Sjoerd Klarenbeek, Eline van der Burg, Bing Xia, Kerstin Hahn, Nicole S. Verkaik, Jeroen Essers, Haico van Attikum, Magdalena B. Rother, Colin Pritchard, Peter Bouwman, Hanneke van der Gulden, Chirantani Mukherjee, Emilia M. Pulver, Ivo J. Huijbers, Anne Paulien Drenth, Stefan J. Roobol, Roebi de Bruijn, Marieke van de Ven, Renske de Korte-Grimmerink, Maria Valeria Lattanzio, Gerarda van de Kamp, Dik C. van Gent
Publikováno v:
Cancer Research, 81(24), 6171-6182. American Association for Cancer Research Inc.
Cancer Research, 81(24), 6171-6182. AMER ASSOC CANCER RESEARCH
Cancer Research, 81(24), 6171-6182. AMER ASSOC CANCER RESEARCH
The BRCA1 tumor suppressor gene encodes a multidomain protein for which several functions have been described. These include a key role in homologous recombination repair (HRR) of DNA double-strand breaks, which is shared with two other high-risk her
Autor:
Chen Wang, Rugang Zhang, Ronny Drapkin, Benjamin G. Bitler, Dajiang Guo, Jianhuang Lin, Heng Liu, Iris Müller, Wei Zhou, Andrew V. Kossenkov, Kristian Helin
Publikováno v:
Cancer Immunol Res
The tumor immune microenvironment is influenced by the epigenetic landscape of the tumor. Here, we have identified the SETDB1–TRIM28 complex as a critical suppressor of antitumor immunity. An epigenetic CRISPR–Cas9 screen of 1,218 chromatin regul
Autor:
Denis Delic, Fei Han, Jaume Capdevila, Katharina Reutner, Rachel Kroe-Barrett, Kai Bernd Stadermann, Aurelie Auguste, Anne Vogt, Isabella Alt, Christina Taubert, Irmgard Hofmann, Bruna de Andrade Pereira, Garazi Serna, Sven Mostböck, Paolo Nuciforo, Rajkumar Ganesan, Christina Pelster, Jark Böttcher, Paul Adam, Melanie Wurm, Otmar Schaaf
Publikováno v:
Molecular Cancer Therapeutics. 20:2250-2261
Despite some impressive clinical results with immune checkpoint inhibitors, the majority of patients with cancer do not respond to these agents, in part due to immunosuppressive mechanisms in the tumor microenvironment. High levels of adenosine in tu
Autor:
Chinthalapally V. Rao, Yuting Zhang, Janani Panneerselvam, Vernon E. Steele, Venkateshwar Madka, Stanley Lightfoot, Gaurav Kumar, Gopal Pathuri, Altaf Mohammed, Chen S. Suen, Vishal Ganta, Ronald A. Lubet, Naveena B. Janakiram
Publikováno v:
Cancer Prevention Research. 14:1009-1020
Colorectal cancer causes over 53,000 deaths annually in the United States. Its rising incidences worldwide and particularly in young adults is a major concern. Here, we evaluated the efficacy of omeprazole that is clinically approved for treating aci
Autor:
Shizhen Zhu, Ting Tao, Itzhak Nissim, Hui Feng, Xiaodan Qin, A. Thomas Look, Jennifer M. Finan, Rindert Missiaen, Guoliang Qing, Jacob Athoe, Amandeep S. Saini, Nicolas Skuli, M. Celeste Simon, Andrew Lam, Annie Kennedy, Nicole M. Anderson
Publikováno v:
Cancer Res
High-risk neuroblastoma remains therapeutically challenging to treat, and the mechanisms promoting disease aggression are poorly understood. Here, we show that elevated expression of dihydrolipoamide S-succinyltransferase (DLST) predicts poor treatme
Autor:
Yasuhisa Murai, Yves Pommier, Se Hyun Kim, Anish Thomas, Frank Zenke, Nobuyuki Takahashi, Fathi Elloumi, Vinodh N. Rajapakse, Ukhyun Jo, Liton Kumar Saha, Astrid Zimmermann, Christopher W. Schultz, Ilya S. Senatorov
Publikováno v:
Molecular Cancer Therapeutics. 20:1431-1441
Although several ATR inhibitors are in development, there are unresolved questions regarding their differential potency, molecular signatures of patients with cancer for predicting activity, and most effective therapeutic combinations. Here, we eluci
Autor:
Daniel L. Flynn, Jarnail Singh, Bryan D. Smith, César Serrano, Alfonso García-Valverde, Anu Gupta
Publikováno v:
Molecular Cancer Therapeutics. 20:1234-1245
The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first-, second-, and third-line targeted therapies, respectively, for meta